OncoSec Medical is a biotechnology & medical research business based in the US. OncoSec Medical shares (ONCS) are listed on the NASDAQ and all prices are listed in US Dollars. OncoSec Medical employs 40 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.00 |
|---|---|
| 52-week range | $0.00 - $0.07 |
| 50-day moving average | $0.42 |
| 200-day moving average | $2.64 |
| Wall St. target price | $110.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-20.31 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.0002 from 2023-08-25
| 1 week (2024-07-15) | N/A |
|---|---|
| 1 month (2024-06-22) | N/A |
| 3 months (2024-04-22) | N/A |
| 6 months (2024-01-22) | N/A |
| 1 year (2023-07-26) | -99.60% |
|---|---|
| 2 years (2022-07-26) | -99.97% |
| 3 years (2021-07-26) | 2.22 |
| 5 years (2019-07-26) | 2.23 |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -92.84% |
| Return on equity TTM | -410.17% |
| Profit margin | 0% |
| Book value | $-1.85 |
| Market Capitalization | $1.7 million |
TTM: trailing 12 months
We're not expecting OncoSec Medical to pay a dividend over the next 12 months.
OncoSec Medical's shares were split on a 1:22 basis on 8 November 2022. So if you had owned 22 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your OncoSec Medical shares – just the quantity. However, indirectly, the new 2100% higher share price could have impacted the market appetite for OncoSec Medical shares which in turn could have impacted OncoSec Medical's share price.
Over the last 12 months, OncoSec Medical's shares have ranged in value from as little as $0.0002 up to $0.0699. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while OncoSec Medical's is 1.9989. This would suggest that OncoSec Medical's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer. Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co. , Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890; and a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine. The company was formerly known as NetVentory Solutions Inc.
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Learn the basics of put options: what they are, how they work and a few examples.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.
Check out the best-performing ETFs so far in 2024.